No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 27.7M | 251M | 272.26M | 225.11M | 253.16M | 228.03M | 235.64M | 230.47M |
| Revenue Growth % | - | - | - | 8.06% | 0.08% | -0.17% | 0.12% | -0.1% | 0.03% | -0.02% |
| Cost of Goods Sold | 776K | 1.15M | 5.6M | 34.6M | 36.81M | 39.37M | 63.7M | 55.09M | 62.68M | 64.4M |
| COGS % of Revenue | - | - | 0.2% | 0.14% | 0.14% | 0.17% | 0.25% | 0.24% | 0.27% | 0.28% |
| Gross Profit | -776K | -1.15M | 22.1M | 216.4M | 235.44M | 185.74M | 189.45M | 172.94M | 172.96M | 166.06M |
| Gross Margin % | - | - | 0.8% | 0.86% | 0.86% | 0.83% | 0.75% | 0.76% | 0.73% | 0.72% |
| Gross Profit Growth % | - | -0.48% | 20.23% | 8.79% | 0.09% | -0.21% | 0.02% | -0.09% | 0% | -0.04% |
| Operating Expenses | 240.3M | 276.6M | 314.5M | 311.1M | 311.04M | 216.14M | 188.16M | 149.22M | 140.31M | 135.1M |
| OpEx % of Revenue | - | - | 11.35% | 1.24% | 1.14% | 0.96% | 0.74% | 0.65% | 0.6% | 0.59% |
| Selling, General & Admin | 31.8M | 53.8M | 106.7M | 146.2M | 141.64M | 118.49M | 116.29M | 89.98M | 89.31M | 80.16M |
| SG&A % of Revenue | - | - | 3.85% | 0.58% | 0.52% | 0.53% | 0.46% | 0.39% | 0.38% | 0.35% |
| Research & Development | 208.5M | 222.8M | 207.8M | 164.9M | 132.85M | 97.65M | 71.87M | 52.24M | 50.38M | 54.94M |
| R&D % of Revenue | - | - | 7.5% | 0.66% | 0.49% | 0.43% | 0.28% | 0.23% | 0.21% | 0.24% |
| Other Operating Expenses | 25K | -400K | -100K | 0 | 36.55M | 0 | 0 | 7M | 625K | 0 |
| Operating Income | -240.3M | -276.6M | -292.4M | -94.7M | -75.59M | -30.4M | 1.29M | 23.72M | 32.64M | 30.97M |
| Operating Margin % | - | - | -10.56% | -0.38% | -0.28% | -0.14% | 0.01% | 0.1% | 0.14% | 0.13% |
| Operating Income Growth % | -0.69% | -0.15% | -0.06% | 0.68% | 0.2% | 0.6% | 1.04% | 17.39% | 0.38% | -0.05% |
| EBITDA | -239.52M | -275.45M | -289.59M | -87.32M | -67.52M | -20.37M | 12.6M | 33.56M | 44.16M | 42.49M |
| EBITDA Margin % | - | - | -10.45% | -0.35% | -0.25% | -0.09% | 0.05% | 0.15% | 0.19% | 0.18% |
| EBITDA Growth % | -0.69% | -0.15% | -0.05% | 0.7% | 0.23% | 0.7% | 1.62% | 1.66% | 0.32% | -0.04% |
| D&A (Non-Cash Add-back) | 776K | 1.15M | 2.81M | 7.38M | 8.08M | 10.03M | 11.3M | 9.84M | 11.52M | 11.52M |
| EBIT | -240.28M | -276.6M | -291.24M | -102.59M | -60.52M | -45.74M | -15.99M | 12.05M | 36M | 36.55M |
| Net Interest Income | 29K | 42K | 536K | -9.19M | -12.17M | -13.56M | -12.65M | -10.78M | -10.72M | -7.73M |
| Interest Income | 1M | 1M | 1.26M | 1.8M | 2.8M | 489K | 160K | 813K | 2.6M | 4.72M |
| Interest Expense | 971K | 958K | 720K | 11M | 15M | 14.05M | 12.81M | 11.59M | 13.33M | 12.45M |
| Other Income/Expense | 996K | 585K | 435K | -18.92M | 53K | -29.39M | -30.09M | -23.26M | -9.97M | -6.87M |
| Pretax Income | -239.3M | -276M | -292M | -113.6M | -75.54M | -59.79M | -28.8M | 457K | 22.67M | 24.1M |
| Pretax Margin % | - | - | -10.54% | -0.45% | -0.28% | -0.27% | -0.11% | 0% | 0.1% | 0.1% |
| Income Tax | -1.75M | -2.15M | -2.21M | -7.92M | 53K | 207K | 324K | 455K | 1.08M | -6.18M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1.01% | 0% | 0.95% | 1.26% |
| Net Income | -239.3M | -276M | -292M | -113.6M | -75.59M | -59.99M | -29.13M | 2K | 21.59M | 30.28M |
| Net Margin % | - | - | -10.54% | -0.45% | -0.28% | -0.27% | -0.12% | 0% | 0.09% | 0.13% |
| Net Income Growth % | -0.69% | -0.15% | -0.06% | 0.61% | 0.33% | 0.21% | 0.51% | 1% | 10794.5% | 0.4% |
| Net Income (Continuing) | -239.28M | -276.01M | -291.95M | -113.58M | -75.59M | -59.99M | -29.13M | 2K | 21.59M | 30.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.45 | -8.29 | -7.86 | -2.99 | -2.13 | -1.52 | -0.72 | 0.02 | 0.45 | 0.62 |
| EPS Growth % | -0.58% | -0.11% | 0.05% | 0.62% | 0.29% | 0.29% | 0.53% | 1.03% | 21.17% | 0.38% |
| EPS (Basic) | -7.45 | -8.29 | -7.86 | -2.99 | -2.13 | -1.52 | -0.72 | 0.02 | 0.46 | 0.62 |
| Diluted Shares Outstanding | 32.13M | 33.3M | 37.17M | 37.94M | 38.77M | 39.58M | 40.64M | 44.93M | 47.55M | 49.1M |
| Basic Shares Outstanding | 32.13M | 33.3M | 37.17M | 37.94M | 38.77M | 39.58M | 40.64M | 44.67M | 47.13M | 48.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 223.55M | 236.47M | 106.39M | 203M | 166.3M | 146.14M | 140.02M | 134.28M | 156.19M | 147.66M |
| Cash & Short-Term Investments | 31.6M | 194.5M | 81.7M | 108.4M | 111.64M | 93.39M | 82.11M | 81.07M | 95.94M | 100.97M |
| Cash Only | 31.6M | 194.5M | 81.7M | 108.4M | 60.04M | 85.29M | 63.13M | 76.2M | 84.58M | 69.22M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 51.61M | 8.1M | 18.98M | 4.87M | 11.35M | 31.75M |
| Accounts Receivable | 0 | 0 | 9.67M | 21.95M | 28.9M | 25.54M | 32.53M | 42.27M | 48.49M | 32.01M |
| Days Sales Outstanding | - | - | 127.42 | 31.92 | 38.74 | 41.42 | 46.9 | 67.66 | 75.11 | 50.7 |
| Inventory | 0 | 0 | 2.03M | 2.63M | 3.17M | 3.45M | 7.11M | 4.53M | 7.08M | 8.72M |
| Days Inventory Outstanding | - | - | 132.25 | 27.69 | 31.43 | 32.02 | 40.73 | 29.99 | 41.23 | 49.44 |
| Other Current Assets | 0 | 0 | 11.69M | 3.85M | 11.74M | 11.75M | 11.43M | 1.95M | 260K | 3.7M |
| Total Non-Current Assets | 16.29M | 16.32M | 59.13M | 56.12M | 68.61M | 98.08M | 86.56M | 87.78M | 74.34M | 65.67M |
| Property, Plant & Equipment | 2.38M | 5.15M | 4.47M | 3.96M | 21.83M | 18.89M | 15.77M | 12.51M | 8.65M | 5.09M |
| Fixed Asset Turnover | - | - | 6.20x | 63.34x | 12.47x | 11.92x | 16.05x | 18.23x | 27.25x | 45.24x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 48.35M | 44.41M | 40.46M | 74.14M | 66.13M | 70.61M | 60.87M | 51.13M |
| Long-Term Investments | 4.31M | 4.32M | 4.32M | 2K | 0 | 0 | 0 | 0 | 2.09M | 0 |
| Other Non-Current Assets | 9.6M | 6.85M | 6.31M | 6.01M | 6.32M | 5.06M | 4.67M | 4.66M | 2.73M | 2.38M |
| Total Assets | 239.84M | 252.79M | 165.53M | 259.12M | 234.91M | 244.22M | 226.59M | 222.06M | 230.53M | 213.33M |
| Asset Turnover | - | - | 0.17x | 0.97x | 1.16x | 0.92x | 1.12x | 1.03x | 1.02x | 1.08x |
| Asset Growth % | 0.47% | 0.05% | -0.35% | 0.57% | -0.09% | 0.04% | -0.07% | -0.02% | 0.04% | -0.07% |
| Total Current Liabilities | 32.44M | 37.46M | 58.34M | 67.11M | 90.84M | 114.25M | 109.59M | 77.48M | 99.38M | 96.11M |
| Accounts Payable | 17.8M | 20.04M | 27.69M | 20.68M | 19.18M | 12.08M | 11.17M | 6.44M | 6.89M | 5.51M |
| Days Payables Outstanding | 8.37K | 6.36K | 1.8K | 218.2 | 190.19 | 111.95 | 64.03 | 42.67 | 40.11 | 31.22 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 14.29M | 0 | 0 | 34M | 45.33M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 27.85M | 40.29M | 5.76M | 15.09M | 11.22M | 13.34M | 43.42M | 39.73M |
| Current Ratio | 6.89x | 6.31x | 1.82x | 3.02x | 1.83x | 1.28x | 1.28x | 1.73x | 1.57x | 1.54x |
| Quick Ratio | 6.89x | 6.31x | 1.79x | 2.99x | 1.80x | 1.25x | 1.21x | 1.67x | 1.50x | 1.45x |
| Cash Conversion Cycle | - | - | -1.55K | -158.59 | -120.02 | -38.51 | 23.6 | 54.98 | 76.22 | 68.92 |
| Total Non-Current Liabilities | 1.39M | 5.5M | 53.88M | 157.7M | 126.61M | 135.92M | 119.44M | 122.97M | 77.7M | 25.1M |
| Long-Term Debt | 0 | 0 | 48.48M | 151.89M | 94.96M | 84.03M | 97.09M | 98.31M | 65.66M | 21.72M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 22.64M | 19.55M | 15.97M | 11.83M | 7.03M | 1.49M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.39M | 5.5M | 5.41M | 5.82M | 9M | 32.34M | 6.38M | 12.83M | 5.01M | 1.88M |
| Total Liabilities | 33.84M | 42.97M | 112.22M | 224.82M | 217.44M | 250.17M | 229.03M | 200.45M | 177.09M | 121.21M |
| Total Debt | 0 | 0 | 48.48M | 151.89M | 120.23M | 120.95M | 116.64M | 114.28M | 111.49M | 74.08M |
| Net Debt | -31.6M | -194.5M | -33.22M | 43.49M | 60.19M | 35.66M | 53.51M | 38.08M | 26.91M | 4.86M |
| Debt / Equity | - | - | 0.91x | 4.43x | 6.88x | - | - | 5.29x | 2.09x | 0.80x |
| Debt / EBITDA | - | - | - | - | - | - | 9.26x | 3.41x | 2.52x | 1.74x |
| Net Debt / EBITDA | - | - | - | - | - | - | 4.25x | 1.13x | 0.61x | 0.11x |
| Interest Coverage | -247.48x | -288.73x | -406.11x | -8.61x | -5.04x | -2.16x | 0.10x | 2.05x | 2.45x | 2.49x |
| Total Equity | 206M | 209.8M | 53.3M | 34.31M | 17.46M | -5.95M | -2.45M | 21.61M | 53.44M | 92.13M |
| Equity Growth % | 0.76% | 0.02% | -0.75% | -0.36% | -0.49% | -1.34% | 0.59% | 9.83% | 1.47% | 0.72% |
| Book Value per Share | 6.41 | 6.30 | 1.43 | 0.90 | 0.45 | -0.15 | -0.06 | 0.48 | 1.12 | 1.88 |
| Total Shareholders' Equity | 206M | 209.8M | 53.3M | 34.31M | 17.46M | -5.95M | -2.45M | 21.61M | 53.44M | 92.13M |
| Common Stock | 3K | 4K | 4K | 4K | 4K | 4K | 4K | 5K | 5K | 5K |
| Retained Earnings | -520.5M | -796.51M | -1.09B | -1.2B | -1.28B | -1.34B | -1.37B | -1.37B | -1.35B | -1.31B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -147K | -13K | -449K | -12K | 62K | 0 | -2K | 0 | -4K | 6K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -154.5M | -141.7M | -172.5M | -24.1M | 22.38M | 800K | 20.65M | -15.83M | 27.01M | 38.92M |
| Operating CF Margin % | - | - | -6.23% | -0.1% | 0.08% | 0% | 0.08% | -0.07% | 0.11% | 0.17% |
| Operating CF Growth % | -1% | 0.08% | -0.22% | 0.86% | 1.93% | -0.96% | 24.81% | -1.77% | 2.71% | 0.44% |
| Net Income | -239.28M | -276.01M | -291.95M | -113.58M | -75.59M | -59.99M | -29.13M | 2K | 21.59M | 30.28M |
| Depreciation & Amortization | 776K | 1.15M | 2.81M | 7.38M | 8.08M | 10.03M | 11.3M | 9.84M | 11.52M | 11.52M |
| Stock-Based Compensation | 94.93M | 117.26M | 108.73M | 86.94M | 57.33M | 36.58M | 32.63M | 11.83M | 10.25M | 8.24M |
| Deferred Taxes | -32K | -10K | 0 | 5K | 0 | 0 | 0 | 0 | 0 | -7.08M |
| Other Non-Cash Items | 179K | 3.37M | -30K | 289K | 9.28M | 1.03M | 7.15M | 7M | 1.51M | -519K |
| Working Capital Changes | -11.07M | 12.54M | 7.94M | -5.14M | 23.28M | 13.16M | -1.31M | -44.5M | -17.85M | -3.54M |
| Change in Receivables | 1.76M | 0 | -9.67M | -11.1M | -8.12M | 2.35M | -5.98M | -7.82M | -8.37M | 16.34M |
| Change in Inventory | 0 | 0 | -2.03M | -596K | -545K | -284K | -3.65M | 2.58M | -2.55M | -1.64M |
| Change in Payables | 2.81M | 2.23M | 7.66M | -7.01M | -1.53M | -7.11M | -902K | -4.73M | 449K | -1.38M |
| Cash from Investing | -85.9M | 142.2M | -15.4M | -57.6M | 5.16M | 23.3M | -10.88M | 7.1M | -19.13M | -20.44M |
| Capital Expenditures | -1.18M | -7.28M | -50.43M | -609K | -306K | -20.05M | 0 | -7M | -140K | -56K |
| CapEx % of Revenue | - | - | 1.82% | 0% | 0% | 0.09% | - | 0.03% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -3.1M | -4K | -15.01M | -170K | 0 | -20.1M | 0 | 0 | -12.5M | 0 |
| Cash from Financing | 233.36M | 162.4M | 75.1M | 108.4M | -67.07M | 100K | -31.93M | 12.22M | 0 | -33.85M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 28.23M | 576K | 25.11M | 3.45M | -12.07M | 32K | -30.43M | -277K | 0 | -666K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -155.68M | -148.98M | -222.93M | -24.71M | 22.07M | -19.25M | 20.65M | -22.83M | 14.37M | 38.86M |
| FCF Margin % | - | - | -8.05% | -0.1% | 0.08% | -0.09% | 0.08% | -0.1% | 0.06% | 0.17% |
| FCF Growth % | -0.98% | 0.04% | -0.5% | 0.89% | 1.89% | -1.87% | 2.07% | -2.11% | 1.63% | 1.7% |
| FCF per Share | -4.85 | -4.47 | -6.00 | -0.65 | 0.57 | -0.49 | 0.51 | -0.51 | 0.30 | 0.79 |
| FCF Conversion (FCF/Net Income) | 0.65x | 0.51x | 0.59x | 0.21x | -0.30x | -0.01x | -0.71x | -7913.50x | 1.25x | 1.29x |
| Interest Paid | 0 | 0 | 0 | 8.05M | 11.74M | 9.7M | 10.34M | 10.32M | 11.63M | 10.77M |
| Taxes Paid | 0 | 0 | 0 | 17K | 53K | 207K | 324K | 384K | 737K | 1.22M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -148.17% | -132.76% | -221.97% | -259.34% | -292.05% | -1042.3% | - | 0.02% | 57.54% | 41.6% |
| Return on Invested Capital (ROIC) | -142.53% | -218.71% | -1239.79% | -145.14% | -72.95% | -42.47% | 2.4% | 32.13% | 34.96% | 26.19% |
| Gross Margin | - | - | 79.78% | 86.22% | 86.48% | 82.51% | 74.84% | 75.84% | 73.4% | 72.06% |
| Net Margin | - | - | -1054.15% | -45.26% | -27.77% | -26.65% | -11.51% | 0% | 9.16% | 13.14% |
| Debt / Equity | - | - | 0.91x | 4.43x | 6.88x | - | - | 5.29x | 2.09x | 0.80x |
| Interest Coverage | -247.48x | -288.73x | -406.11x | -8.61x | -5.04x | -2.16x | 0.10x | 2.05x | 2.45x | 2.49x |
| FCF Conversion | 0.65x | 0.51x | 0.59x | 0.21x | -0.30x | -0.01x | -0.71x | -7913.50x | 1.25x | 1.29x |
| Revenue Growth | - | - | - | 806.14% | 8.47% | -17.32% | 12.46% | -9.92% | 3.34% | -2.19% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Product | 200.49M | 211.62M | - | 189.06M | 200.02M | 203.11M | 195.19M |
| Product Growth | - | 5.55% | - | - | 5.80% | 1.54% | -3.90% |
| Royalty | - | 391K | 5.68M | 12.34M | 28.01M | 32.53M | 35.28M |
| Royalty Growth | - | - | 1353.20% | 117.19% | 126.95% | 16.15% | 8.46% |
| License | 50.5M | 60.25M | 2.5M | 51.75M | - | - | - |
| License Growth | - | 19.31% | -95.85% | 1970.00% | - | - | - |
Puma Biotechnology, Inc. (PBYI) has a price-to-earnings (P/E) ratio of 10.3x. This may indicate the stock is undervalued or faces growth challenges.
Puma Biotechnology, Inc. (PBYI) reported $212.0M in revenue for fiscal year 2024.
Puma Biotechnology, Inc. (PBYI) saw revenue decline by 2.2% over the past year.
Yes, Puma Biotechnology, Inc. (PBYI) is profitable, generating $37.0M in net income for fiscal year 2024 (13.1% net margin).
Puma Biotechnology, Inc. (PBYI) has a return on equity (ROE) of 41.6%. This is excellent, indicating efficient use of shareholder capital.
Puma Biotechnology, Inc. (PBYI) generated $42.9M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.